



CAR-TALKING

News dal mondo CAR-T

Verona, Hotel Indigo Verona – Grand Hotel Des Arts
28 aprile 2023


Caso Clinico 1

Un buon esempio di
«network»


*Marcello Riva
UOC Ematologia, Ospedale
San Bortolo Vicenza*

Disclosure: I have no actual or potential conflict of interest in relation to this presentation.


- Male, 54 yrs
- Past medical history: 2013, splenic marginal zone lymphoma (SMZL), low-tumor burden (HCV neg), in observartion
- July 2020: diagnosis of DLBCL (nonGCB), stage IVB (bone marrow, pancreas, rhinopharynx, lymphadenopathy on both sides of the diaphragm), aalPI high-int. risk (2 points), CNS-IPI int-risk (3 points)
- FISH: translocation involving Myc and Bcl-6 (*double hit lymphoma*)




- August 2022 (relapse): DLBCL, nonGCB, stage IIA, aaIPI low-int. risk (1 point). FISH: translocation involving Myc and Bcl-6 (*double hit lymphoma*)
- Progression after two previous lines of treatment:
 - After evaluation in reference center, he is proposed for anti-CD19 CAR-T therapy
 - Bridging therapy: one cycle of Pola-BR + radiation therapy



- 04/11/2022 to 10/11/2022: bridging radiation therapy (20 Gy in 5 fractions)
- Restaging pre CAR-T (14/11/2022): complete metabolic response (DS3)
- CAR-HEMATOTOX: low-risk (1 point)
- Axicabtagene ciloleucel infusion 24/11/2022



- 03/12/2022 to 07/12/2022: CRS G1 (2 Tocilizumab doses), no ICANS
- From 02/12/2022, CAR-T expansion in peripheral blood (max expansion: 34,83 CAR-T cells/uL, days 13)
- Response after CAR-T (+30 days and +90 days): complete metabolic response (DS1)
- No cytopenias or late complication after CAR-T infusion



Conclusion:

- Working together and collaboration among centres (hub & referral)
- Curative potential role of axi-cel in a subset of patients with aggressive B-cell lymphoma
- Response to bridging therapy increase the durable remission post CAR-T
- Axi-cel durable responses were associated with low tumor burden and low systemic inflammation
- Durable responses were associated with expansion of CAR-T
- Role of PET/CT response at 30 and 90 days

CAR-T Team Vicenza

Ematologia

Maria Chiara Tisi

Marcello Riva

Alberto Tosetto

Carlo Borghero

Francesca Elice

Sabrina Carboniero (inf coord)

Aferesi

Manuela Rigno

Gabriella Errigo

Monica Castelli

Laboratorio di Manip e Criopr

Chiara Lievore

Cinzia Tagliaferri

Monica Mantia

Farmacia

Stefania Pretto

Giulia Busa

Marta Cappelini

Neurologia

Giulia Zarantonello

Rianimazione

Vinicio Danzi

Marina Alessandra Martin

Cardiologia

Francesco Caprioglio

Marco Morato

Malattia Infettive

Vinicio Manfrin

Marta Mascarello

Veronica Del Punta



**Dr. Laveder, Dr. P.M. Stefani.
Infermieri Professionali
dell'ematologia e tutti i pazienti.**

